170 related articles for article (PubMed ID: 37885006)
21. Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma.
D'Costa NM; Cina D; Shrestha R; Bell RH; Lin YY; Asghari H; Monjaras-Avila CU; Kollmannsberger C; Hach F; Chavez-Munoz CI; So AI
Sci Rep; 2020 Feb; 10(1):2026. PubMed ID: 32029828
[TBL] [Abstract][Full Text] [Related]
22. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
Front Immunol; 2022; 13():954440. PubMed ID: 36059510
[TBL] [Abstract][Full Text] [Related]
23. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
[TBL] [Abstract][Full Text] [Related]
24. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract][Full Text] [Related]
26. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
27. Using Genomic and Transcriptome Analyses to Identify the Role of the Oxidative Stress Pathway in Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance.
Che X; Qi X; Xu Y; Wang Q; Wu G
Oxid Med Cell Longev; 2021; 2021():5561124. PubMed ID: 34721758
[TBL] [Abstract][Full Text] [Related]
28. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
[TBL] [Abstract][Full Text] [Related]
31. Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma.
Pan H; Lu W; Zhang M; Liu C
Front Oncol; 2023; 13():1131191. PubMed ID: 37182129
[TBL] [Abstract][Full Text] [Related]
32. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
33. Establishment of a Seven-Gene Signature Associated with CD8
Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
[TBL] [Abstract][Full Text] [Related]
34. Supervised Learning and Multi-Omics Integration Reveals Clinical Significance of Inner Membrane Mitochondrial Protein (IMMT) in Prognostic Prediction, Tumor Immune Microenvironment and Precision Medicine for Kidney Renal Clear Cell Carcinoma.
Chen CC; Chu PY; Lin HY
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240154
[TBL] [Abstract][Full Text] [Related]
35. Prognostic prediction and immunotherapy response analysis of the fatty acid metabolism-related genes in clear cell renal cell carcinoma.
Yao Q; Zhang X; Wei C; Chen H; Xu Q; Chen J; Chen D
Heliyon; 2023 Jun; 9(6):e17224. PubMed ID: 37360096
[TBL] [Abstract][Full Text] [Related]
36. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
37. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
[No Abstract] [Full Text] [Related]
38. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Uemura M; Tomita Y; Miyake H; Hatakeyama S; Kanayama HO; Numakura K; Takagi T; Kato T; Eto M; Obara W; Uemura H; Choueiri TK; Motzer RJ; Fujii Y; Kamei Y; Umeyama Y; di Pietro A; Oya M
Cancer Sci; 2020 Mar; 111(3):907-923. PubMed ID: 31883418
[TBL] [Abstract][Full Text] [Related]
39. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
[TBL] [Abstract][Full Text] [Related]
40. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
Tamura K; Osawa T; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Sugimoto M; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Komiyama M; Tanaka K; Yokomizo A; Kohei N; Shinohara N; Miyake H;
Jpn J Clin Oncol; 2021 Apr; 51(5):810-818. PubMed ID: 33479762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
